Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Advances in the treatment of primary and secondary immune deficiences

Advances in the treatment of primary and secondary immune deficiences URRENT Advances in the treatment of primary and PINION secondary immune deficiences Srini Kaveri Intravenous immunoglobulins (IVIgs) are a thera- patients with autoimmune haemophilia. This effect peutic preparation of pooled normal polyspecific was attributed to the presence in IVIg of antiidiotypic human IgGs obtained from large numbers of antibodies against anti-Factor VIII autoantibodies [7]. healthy donors. The preparation contains anti- Subsequently, several other groups demonstrated bodies to nonself-antigens (microbial antigens), the existence of antiidiotypic antibodies against a antibodies to self-antigens (natural autoantibodies), wide range of pathogenic autoantibodies [6]. and antibodies that recognize other antibodies, also A proposed anti-inflammatory mechanism of known as antiidiotypic antibodies [1,2]. action for IVIg was an anticomplement scavenging In order to explain the therapeutic benefit effect. Indeed, binding of IVIg with complement conferred by IVIg in a large number of hetero- inhibits the generation of the C5b-9 membrane geneous disorders, several mutually nonexclusive attack complex and subsequent complement- mechanisms of action have been proposed, in the mediated tissue damage, such as that which occurs contexts of primary immune deficiency (PID), auto- in muscle microvasculature during dermatomyositis immunity, and inflammation. In PID, it is generally [8]. In the course of the 1990s, it was thought believed http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in Allergy and Clinical Immunology Wolters Kluwer Health

Advances in the treatment of primary and secondary immune deficiences

Download PDF
28 pages

Loading next page...
 
/lp/wolters-kluwer-health/advances-in-the-treatment-of-primary-and-secondary-immune-deficiences-TScWVazsoD

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1528-4050
eISSN
1473-6322

Abstract

URRENT Advances in the treatment of primary and PINION secondary immune deficiences Srini Kaveri Intravenous immunoglobulins (IVIgs) are a thera- patients with autoimmune haemophilia. This effect peutic preparation of pooled normal polyspecific was attributed to the presence in IVIg of antiidiotypic human IgGs obtained from large numbers of antibodies against anti-Factor VIII autoantibodies [7]. healthy donors. The preparation contains anti- Subsequently, several other groups demonstrated bodies to nonself-antigens (microbial antigens), the existence of antiidiotypic antibodies against a antibodies to self-antigens (natural autoantibodies), wide range of pathogenic autoantibodies [6]. and antibodies that recognize other antibodies, also A proposed anti-inflammatory mechanism of known as antiidiotypic antibodies [1,2]. action for IVIg was an anticomplement scavenging In order to explain the therapeutic benefit effect. Indeed, binding of IVIg with complement conferred by IVIg in a large number of hetero- inhibits the generation of the C5b-9 membrane geneous disorders, several mutually nonexclusive attack complex and subsequent complement- mechanisms of action have been proposed, in the mediated tissue damage, such as that which occurs contexts of primary immune deficiency (PID), auto- in muscle microvasculature during dermatomyositis immunity, and inflammation. In PID, it is generally [8]. In the course of the 1990s, it was thought believed

Journal

Current Opinion in Allergy and Clinical Immunology – Wolters Kluwer Health

Published: Jul 1, 2013

There are no references for this article.